Benitec Biopharma Inc.BNTC
What Benitec Biopharma Inc. does.
Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. We are developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy ("OPMD"), a chronic, life-threatening genetic disorder.
BB-301 is an AAV-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a functional gene (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called “silence and replace.” The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. BB-301 has been granted Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union.
We believe that this novel mechanistic profile of the current and future investigational agents developed by Benitec could facilitate the achievement of robust and durable clinical activity while greatly reducing the frequency of drug administration traditionally expected for medicines employed for the management of chronic diseases. Additionally, the achievement of permanent gene silencing and gene replacement may significantly reduce the risk of patient non-compliance during the course of medical management of potentially fatal clinical disorders. We will require additional financing to progress our product candidates through future inflection points.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $59,000 | $73,000 | $75,000 | $0 | — | — |
| Net income | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M | -$45.5M |
| Free cash flow | -$13.1M | -$15.9M | -$18.0M | -$19.6M | -$23.6M | -$16.6M |
More on BNTC.
- Benitec Biopharma Inc. summary
- Benitec Biopharma Inc. financial statements
- Benitec Biopharma Inc. key metrics
- Benitec Biopharma Inc. health scores and style box
- Benitec Biopharma Inc. earnings
- Benitec Biopharma Inc. dividends
- Benitec Biopharma Inc. valuation
- Benitec Biopharma Inc. ownership and insiders
- Benitec Biopharma Inc. peers
Figures from Benitec Biopharma Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.